Synergy Pharmaceuticals Inc.

Stability & Safety

Synergy’s approach is based on a natural hormone the body produces in the small intestine to activate critical gastrointestinal functions- uroguanylin. We have discovered proprietary analogs of uroguanylin and are developing them as targeted therapies that mimic natural activity to treat GI disorders.

Learn more about Synergy's Approach

Drug Pipeline

Synergy’s Proprietary Platform

Both our lead drug, plecanatide, and our next-generation candidate, SP-333, are proprietary analogs of the body’s naturally occurring gastrointestinal (GI) hormone, uroguanylin, and represent a novel approach to the treatment of GI diseases and disorders. Plecanatide is in late stage clinical trials for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). SP-333 is currently in clinical trials for opioid-induced constipation (OIC) and is also being studied for treatment of ulcerative colitis (UC).

Learn More about Synergy's Drug Pipeline
Compound Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Marketed
Plecanatide
(sp-304)
CIC
IBS-C
SP-333 OIC
UC
Go to News & Media

Latest News & Events

Go To Investor Relations

Investor Relations

Overview

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders.

Recent Documents

SGYP NASDAQ
Volume
Market Cap
Change